Rejuvenate Bio is tackling aging and age-related diseases through targeted gene therapies, believing that aging results from the dysregulation of genes and proteins and that “reregulating genes back to the healthy state people had when they were younger” will reverse aging, according to CSO Noah Davidson. Based on the work of acclaimed scientist George Church, whose lab in 2019 successfully treated obesity, type II diabetes, heart failure, and renal failure in mice, the company aims to target multiple diseases with a single treatment. The company is pursuing a dual strategy whereby initial veterinary commercialization will not only provide revenue but also assist IND-enabling studies for humans.
Rejuvenate Bio’s lead therapy, RJB-01, targets the genes FGF21 and sTGFßR2 with an adeno-associated virus (AAV) delivery system in order to upregulate FGF21 and downregulate TGFß1 for the treatment of heart failure. The company launched a pilot study of RJB-01 in Cavalier King Charles Spaniels for Mitral Valve Disease (MVD) in 2019. It is expected to enter human trials and be commercialized in animals in 2023.
Rejuvenate Bio has a second candidate, RJB-02, targeting FGF21 and αKlotho for osteoarthritis, in preclinical development.
In April 2021, Rejuvenate Bio raised over $10 million in Series A funding.